SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer sub	niect to
	JCCI IO
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* O'NEIL PATRICK R.			2. Issuer Name and Ticker or Trading Symbol <u>IONIS PHARMACEUTICALS INC</u> [IONS]		tionship of Reporting Person(s) to Issuer (all applicable) Director 10% Owner Officer (give title Other (specify below) below)		
(Last) C/O IONIS PH 2855 GAZELL		(Middle) TCALS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 12/01/2017		SVP, Legal & Ger	,	
(Street) CARLSBAD	CA (State)	92010	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Fili Form filed by One Re Form filed by More th Person	porting Person	
	(State)	(Zip)		1			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (ction Disposed Of (D) (Instr. 3,				5. Amount of Securities Beneficially Owned Following Benorted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)		
12/01/2017	12/01/2017	M ⁽¹⁾		1,000(1)	Α	\$10.82	11,433	D			
12/01/2017	12/01/2017	S ⁽¹⁾		1,000(1)	D	\$55.5 ⁽²⁾	10,433	D			
	Date (Month/Day/Year)	Date (Month/Day/Year)Execution Date, if any (Month/Day/Year)12/01/201712/01/2017	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transa Code (8) 12/01/2017 12/01/2017 M ⁽¹⁾	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) 12/01/2017 12/01/2017 M ⁽¹⁾	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. Disposed Of (S) 12/01/2017 12/01/2017 M ⁽¹⁾ V Amount	$ \begin{array}{ c c c c c c } \hline Date & Execution Date, & Iransaction & Disposed Of (D) (Instr. & Observed $	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 4 and 5) Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 12/01/2017 12/01/2017 M ⁽¹⁾ 1,000 ⁽¹⁾ A \$10.82 11,433	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		n of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date		6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares												
Employee Stock Option (right to buy)	\$10.82	12/01/2017	12/01/2017	М			1,000	01/02/2017	01/01/2020	Common Stock	1,000	\$0	700	D									

Explanation of Responses:

1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$55.45 to \$55.55, inclusive. The reporting person undertakes to provide to Inis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Remarks:

<u>/s/B. L</u>	<u>ynne</u>	Parsh	<u>all,</u>	attorney-
in-fact				

12/01/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.